Drug Profile


Alternative Names: CEM-101; OP-1068; T-4288

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Optimer Pharmaceuticals
  • Developer Cempra Pharmaceuticals; Melinta Therapeutics; Toyama Chemical
  • Class Anti-infectives; Antibacterials; Antimalarials; Heterocyclic bicyclo compounds; Ketolides; Macrolides; Oxazoles; Pyrans; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Community-acquired pneumonia
  • Phase III Bronchitis; Chlamydial infections; Gonorrhoea; Otorhinolaryngological infections; Respiratory tract infections; Sinusitis; Urethritis
  • Phase II Chronic obstructive pulmonary disease; Non-alcoholic steatohepatitis
  • Phase I Bacterial infections
  • Preclinical Eye disorders; Obstetric and gynaecological infections; Otitis media
  • No development reported Anthrax; Cystic fibrosis; Enterococcal infections; Legionella infections; Malaria; Mycobacterium avium complex infections; Mycoplasma infections; Tularaemia

Most Recent Events

  • 06 Nov 2017 Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Anthrax in USA
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bacterial-infections(Adjunctive treatment, In adolescents) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top